Basic Stats
| CIK | 1838821 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to ARYA Sciences Acquisition Corp IV
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001‑40122 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as spe |
|
| July 26, 2024 |
false0001838821NASDAQ00018388212024-07-262024-07-26 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2024 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of inco |
|
| July 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2024 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorporatio |
|
| July 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2024 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorporatio |
|
| July 15, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D |
|
| July 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): June 28, 2024 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorporatio |
|
| July 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): June 28, 2024 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorporatio |
|
| July 2, 2024 |
Exhibit 10.1 THIS CONVERTIBLE PROMISSORY NOTE (THIS “NOTE”) AND THE SECURITIES INTO WHICH IT MAY BE CONVERTED HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE. THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFER |
|
| July 2, 2024 |
Exhibit 10.1 THIS CONVERTIBLE PROMISSORY NOTE (THIS “NOTE”) AND THE SECURITIES INTO WHICH IT MAY BE CONVERTED HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE. THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFER |
|
| June 28, 2024 |
SC 13G/A 1 tm2417765d24sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1) Arya Sciences Acquisition Corp. IV (Name of Issuer) Class A Ordinary Shares, par value $0.0001 pe |
|
| June 25, 2024 |
TO BUSINESS COMBINATION AGREEMENT Exhibit 2.1 CONSENT AND AMENDMENT NO. 1 TO BUSINESS COMBINATION AGREEMENT This CONSENT AND AMENDMENT NO. 1 to the BUSINESS COMBINATION AGREEMENT, dated as of June 25, 2024 (this “Consent and Amendment”), is made by and between ARYA Sciences Acquisition Corp IV, a Cayman Islands exempted company (“ARYA”) and Adagio Medical, Inc., a Delaware corporation (the “Company”). ARYA and the Company shall ea |
|
| June 25, 2024 |
Exhibit 10.2 SUBSCRIPTION AGREEMENT ARYA Sciences Acquisition Corp IV 51 Astor Place, 10th Floor New York, New York 10002 Ladies and Gentlemen: This Subscription Agreement (this “Subscription Agreement”) is being entered into as of the date set forth on the signature page hereto, by and between Aja Holdco, Inc., a Delaware corporation and prior to the Closing Date (as defined below), a wholly owne |
|
| June 25, 2024 |
Exhibit 10.1 SUBSCRIPTION AGREEMENT ARYA Sciences Acquisition Corp IV 51 Astor Place, 10th Floor New York, New York 10002 Ladies and Gentlemen: This Subscription Agreement (this “Subscription Agreement”) is being entered into as of the date set forth on the signature page hereto, by and between Aja Holdco, Inc., a Delaware corporation and prior to the Closing Date (as defined below), a wholly owne |
|
| June 25, 2024 |
Exhibit 10.2 SUBSCRIPTION AGREEMENT ARYA Sciences Acquisition Corp IV 51 Astor Place, 10th Floor New York, New York 10002 Ladies and Gentlemen: This Subscription Agreement (this “Subscription Agreement”) is being entered into as of the date set forth on the signature page hereto, by and between Aja Holdco, Inc., a Delaware corporation and prior to the Closing Date (as defined below), a wholly owne |
|
| June 25, 2024 |
Exhibit 10.1 SUBSCRIPTION AGREEMENT ARYA Sciences Acquisition Corp IV 51 Astor Place, 10th Floor New York, New York 10002 Ladies and Gentlemen: This Subscription Agreement (this “Subscription Agreement”) is being entered into as of the date set forth on the signature page hereto, by and between Aja Holdco, Inc., a Delaware corporation and prior to the Closing Date (as defined below), a wholly owne |
|
| June 25, 2024 |
AMENDMENT NO. 1 TO SUBSCRIPTION AGREEMENT Exhibit 10.3 AMENDMENT NO. 1 TO SUBSCRIPTION AGREEMENT ARYA Sciences Acquisition Corp IV 51 Astor Place, 10th Floor New York, New York 10002 Ladies and Gentlemen: This amendment (this “Amendment”) to the Subscription Agreement (the “Subscription Agreement”), dated February 13, 2024, by and between Aja Holdco, Inc., a Delaware corporation (“ListCo”), ARYA Sciences Acquisition Corp IV, a Cayman Isla |
|
| June 25, 2024 |
AMENDMENT NO. 1 TO SUBSCRIPTION AGREEMENT Exhibit 10.3 AMENDMENT NO. 1 TO SUBSCRIPTION AGREEMENT ARYA Sciences Acquisition Corp IV 51 Astor Place, 10th Floor New York, New York 10002 Ladies and Gentlemen: This amendment (this “Amendment”) to the Subscription Agreement (the “Subscription Agreement”), dated February 13, 2024, by and between Aja Holdco, Inc., a Delaware corporation (“ListCo”), ARYA Sciences Acquisition Corp IV, a Cayman Isla |
|
| June 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2024 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorporatio |
|
| June 25, 2024 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2024 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorporatio |
|
| June 25, 2024 |
TO BUSINESS COMBINATION AGREEMENT Exhibit 2.1 CONSENT AND AMENDMENT NO. 1 TO BUSINESS COMBINATION AGREEMENT This CONSENT AND AMENDMENT NO. 1 to the BUSINESS COMBINATION AGREEMENT, dated as of June 25, 2024 (this “Consent and Amendment”), is made by and between ARYA Sciences Acquisition Corp IV, a Cayman Islands exempted company (“ARYA”) and Adagio Medical, Inc., a Delaware corporation (the “Company”). ARYA and the Company shall ea |
|
| June 11, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2024 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorporatio |
|
| June 11, 2024 |
ADAGIO MEDICAL Investor Presentation | June 2024 1 Exhibit 99.1 ADAGIO MEDICAL Investor Presentation | June 2024 1 DISCLAIMER This investor presentation (together with the oral statements made in connection herewith, this “Presentation”) is for informational purposes only to assist interested parties in making their own evaluation with respect to the proposed business combination and any related transaction, including with the PIPE financing descr |
|
| June 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2024 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorporatio |
|
| June 11, 2024 |
ADAGIO MEDICAL Investor Presentation | June 2024 1 Exhibit 99.1 ADAGIO MEDICAL Investor Presentation | June 2024 1 DISCLAIMER This investor presentation (together with the oral statements made in connection herewith, this “Presentation”) is for informational purposes only to assist interested parties in making their own evaluation with respect to the proposed business combination and any related transaction, including with the PIPE financing descr |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): June 2, 2024 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorporation |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): June 2, 2024 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorporation |
|
| May 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ARYA SCIENCES ACQUISITION CORP IV (Exact name of reg |
|
| May 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ARYA SCIENCES ACQUISITION CORP IV (Exact name of regis |
|
| May 16, 2024 |
Adagio Medical Announces First European Commercial Procedures and Filed by Aja HoldCo, Inc. pursuant to Rule 425 under the Securities Act of 1933, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Form S-4 File No. (333-278811) Subject Company: ARYA Sciences Acquisition Corp IV (Commission File No. 001-40122) Date: May 16, 2024 Adagio Medical Announces First European Commercial Procedures and Commencement of U.S. FDA Pivotal IDE |
|
| May 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) ☐ Form 10-K ☐ Form N-CSR ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N- CEN For Period Ended: March 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Perio |
|
| May 10, 2024 |
ARYD / ARYA Sciences Acquisition Corp IV / GLAZER CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 ARYA SCIENCES ACQUISITION CORP IV (Name of Issuer) Class A Ordinary Share, $0.0001 par value per share (Title of Class of Securities) G31659108 (CUSIP Number) April 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): May 2, 2024 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorporation) |
|
| May 2, 2024 |
Exhibit 99.1 April 26, 2024 Adagio Medical Inc. Nabil Jubran Chief Compliance Officer 26051 Merit Circle, Suite 102 Laguna Hills, California 92653 Re: G220229/S002/A001 Trade/Device Name: vCLAS™ Cryoablation System (vCLAS™ Cryoablation Catheter, VT Cryoablation Console) Dated: March 27, 2024 Received: March 28, 2024 CMS Category: B Annual Report Due: December 8, 2024 Dear Nabil Jubran: The Food an |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2024 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorporati |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2024 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorporati |
|
| May 2, 2024 |
Exhibit 99.1 April 26, 2024 Adagio Medical Inc. Nabil Jubran Chief Compliance Officer 26051 Merit Circle, Suite 102 Laguna Hills, California 92653 Re: G220229/S002/A001 Trade/Device Name: vCLAS™ Cryoablation System (vCLAS™ Cryoablation Catheter, VT Cryoablation Console) Dated: March 27, 2024 Received: March 28, 2024 CMS Category: B Annual Report Due: December 8, 2024 Dear Nabil Jubran: The Food an |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): May 2, 2024 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorporation) |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2024 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorporati |
|
| April 24, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2024 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorporati |
|
| April 24, 2024 |
Exhibit 99.1 ADAGIO MEDICAL Investor Presentation | April 2024 1 DISCLAIMER 2 PRIVATE AND CONFIDENTIAL This investor presentation (together with the oral statements made in connection herewith, this “Presentation”) is for informational purposes only to assist interested parties in making their own evaluation with respect to the proposed business combination and any related transaction, including w |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): April 2, 2024 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorporatio |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): April 2, 2024 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorporatio |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2024 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorporati |
|
| March 29, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2024 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorporati |
|
| March 29, 2024 |
ARYA SCIENCES ACQUISITION CORP IV DESCRIPTION OF SECURITIES Exhibit 4.2 ARYA SCIENCES ACQUISITION CORP IV DESCRIPTION OF SECURITIES The following summary of the material terms of the securities of ARYA Sciences Acquisition Corp IV is not intended to be a complete summary of the rights and preferences of such securities and is subject to and qualified by reference to our amended and restated memorandum and articles of association and applicable Cayman Islan |
|
| March 29, 2024 |
Subsidiaries of ARYA Sciences Acquisition Corp IV Exhibit 21 Subsidiaries of ARYA Sciences Acquisition Corp IV Aja Holdco, Inc. |
|
| March 29, 2024 |
CLAWBACK POLICY ARYA SCIENCES ACQUISITION CORP IV Exhibit 97 CLAWBACK POLICY ARYA SCIENCES ACQUISITION CORP IV PURPOSE ARYA Sciences Acquisition Corp IV (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40122 ARYA SCIENCES ACQ |
|
| March 25, 2024 |
Filed by Aja HoldCo, Inc. pursuant to Rule 425 under the Securities Act of 1933, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Form S-4 File No. (333 - ) Subject Company: ARYA Sciences Acquisition Corp IV (Commission File No. 001-40122) Date: March 25, 2024 Adagio Medical Announces CE Mark Approval of VT Cryoablation System, Plans for Immediate Commercializatio |
|
| February 28, 2024 |
Exhibit 3.1 Registrar of Companies Ground Floor Government Administration Building 133 Elgin Avenue PO Box 123 George Town Grand Cayman KY1-9000 ARYA Sciences Acquisition Corp IV (ROC #365460) (the “Company”) TAKE NOTICE that at an Extraordinary General Meeting of the shareholders of the Company held at 11:00 a.m., Eastern Time, on 27 February 2024, at the offices of Kirkland & Ellis LLP located a |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2024 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorpor |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2024 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorpor |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of |
|
| February 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| February 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2024 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of |
|
| February 15, 2024 |
DEFA14A 1 ny20020899x8defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by |
|
| February 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| February 14, 2024 |
FORM OF CONVERT REGISTRATION RIGHTS AGREEMENT Exhibit 10.12 FORM OF CONVERT REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of [], 2024, is by and among Aja Holdco, Inc., a Delaware corporation with offices located at [ADDRESS] (the “Company”), and the undersigned buyers (each, a “Buyer,” and collectively, the “Buyers”). RECITALS A. In connection with the Securities Purchase Agreement by and among |
|
| February 14, 2024 |
[FORM OF SENIOR SECURED CONVERTIBLE NOTE] Exhibit 10.16 EXHIBIT A [FORM OF SENIOR SECURED CONVERTIBLE NOTE] NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE AB |
|
| February 14, 2024 |
[FORM OF SENIOR SECURED CONVERTIBLE NOTE] Exhibit 10.16 EXHIBIT A [FORM OF SENIOR SECURED CONVERTIBLE NOTE] NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE AB |
|
| February 14, 2024 |
ARYD / ARYA Sciences Acquisition Corp IV / TENOR CAPITAL MANAGEMENT Co., L.P. Passive Investment SC 13G 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* ARYA SCIENCES ACQUISITION CORP. IV (Name of Issuer) Class A Ordinary Share, $0.0001 par value (Title of Class of Securities) G31659108 (CUSIP Number) April 10, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d |
|
| February 14, 2024 |
Form of Open Market Purchase Subscription Agreement SUBSCRIPTION AGREEMENT Exhibit 10.5 Form of Open Market Purchase Subscription Agreement SUBSCRIPTION AGREEMENT ARYA Sciences Acquisition Corp IV 51 Astor Place, 10th Floor New York, New York 10002 Ladies and Gentlemen: This Subscription Agreement (this “Subscription Agreement”) is being entered into as of the date set forth on the signature page hereto, by and between Aja Holdco, Inc., a Delaware corporation and prior t |
|
| February 14, 2024 |
Exhibit 10.15 THIS CONVERTIBLE PROMISSORY NOTE (“NOTE”) AND THE SECURITIES INTO WHICH IT MAY BE CONVERTED HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE. THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED |
|
| February 14, 2024 |
FORM OF CONVERTIBLE SECURITIES PURCHASE AGREEMENT Exhibit 10.7 FORM OF CONVERTIBLE SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of February [●], 2024 (the “Subscription Date”), is by and among Aja Holdco, Inc., a Delaware corporation with offices located at 51 Astor Place, 10th Floor, New York, New York 10003 (the “Company”), ARYA Sciences Acquisition Corp IV, a company organized under the laws of t |
|
| February 14, 2024 |
Exhibit 10.1 SPONSOR LETTER AGREEMENT This SPONSOR LETTER AGREEMENT (this “Agreement”), dated as of February 13, 2024, is made by and among Aja HoldCo, Inc., a Delaware corporation (“HoldCo”), ARYA Sciences Holdings IV, an exempted company incorporated in the Cayman Islands with limited liability (the “ARYA Sponsor”), ARYA Sciences Acquisition Corp IV, an exempted company incorporated in the Cayma |
|
| February 14, 2024 |
Form of Non-Redemption Subscription Agreement SUBSCRIPTION AGREEMENT Exhibit 10.4 Form of Non-Redemption Subscription Agreement SUBSCRIPTION AGREEMENT ARYA Sciences Acquisition Corp IV 51 Astor Place, 10th Floor New York, New York 10002 Ladies and Gentlemen: This Subscription Agreement (this “Subscription Agreement”) is being entered into as of the date set forth on the signature page hereto, by and between Aja Holdco, Inc., a Delaware corporation and prior to the |
|
| February 14, 2024 |
Exhibit 10.10 FORM OF CONVERT GUARANTY This GUARANTY, dated as of , 2024 (this “Guaranty”), is made by each of the undersigned (each a “Guarantor”, and collectively, the “Guarantors”), in favor of Allegro Management LLC, in its capacity as collateral agent (in such capacity, the “Collateral Agent” as hereinafter further defined) for the “Buyers” party to the Securities Purchase Agreement (each as |
|
| February 14, 2024 |
Exhibit 10.1 SPONSOR LETTER AGREEMENT This SPONSOR LETTER AGREEMENT (this “Agreement”), dated as of February 13, 2024, is made by and among Aja HoldCo, Inc., a Delaware corporation (“HoldCo”), ARYA Sciences Holdings IV, an exempted company incorporated in the Cayman Islands with limited liability (the “ARYA Sponsor”), ARYA Sciences Acquisition Corp IV, an exempted company incorporated in the Cayma |
|
| February 14, 2024 |
Exhibit 99.2 ADAGIO MEDICAL Investor Presentation | February 2024 DISCLAIMER 2 This investor presentation (together with the oral statements made in connection herewith, this “Presentation”) is for informational purposes only to assist interested parties in making their own evaluation with respect to the proposed business combination and any related transaction, including with the PIPE financing d |
|
| February 14, 2024 |
FORM OF CONVERT REGISTRATION RIGHTS AGREEMENT Exhibit 10.12 FORM OF CONVERT REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of [], 2024, is by and among Aja Holdco, Inc., a Delaware corporation with offices located at [ADDRESS] (the “Company”), and the undersigned buyers (each, a “Buyer,” and collectively, the “Buyers”). RECITALS A. In connection with the Securities Purchase Agreement by and among |
|
| February 14, 2024 |
Exhibit 10.9 [FORM OF WARRANT] NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRAT |
|
| February 14, 2024 |
Form of Open Market Purchase Subscription Agreement SUBSCRIPTION AGREEMENT Exhibit 10.5 Form of Open Market Purchase Subscription Agreement SUBSCRIPTION AGREEMENT ARYA Sciences Acquisition Corp IV 51 Astor Place, 10th Floor New York, New York 10002 Ladies and Gentlemen: This Subscription Agreement (this “Subscription Agreement”) is being entered into as of the date set forth on the signature page hereto, by and between Aja Holdco, Inc., a Delaware corporation and prior t |
|
| February 14, 2024 |
Exhibit 10.13 Investor Rights Agreement This Investor Rights Agreement (this “Agreement”), dated as of February 13, 2024, is among Aja Holdco, Inc., a Delaware corporation (“Company”), ARYA Sciences Acquisition Corp IV, a Cayman Islands exempted company (the “SPAC”), ARYA Sciences Holdings IV, a Cayman Islands exempted limited company (the “Sponsor”), the Independent Directors (as defined herein), |
|
| February 14, 2024 |
Exhibit 10.8 NOTE PURCHASE AGREEMENT THIS NOTE PURCHASE AGREEMENT (this “Agreement”) is made as of February 13, 2024, by and between Adagio Medical, Inc., a Delaware corporation (the “Company”), Aja Holdco, Inc., a Delaware corporation (“New Adagio”), and Perceptive Life Sciences Master Fund, Ltd. (the “Investor”). WHEREAS, the Company has entered into a Business Combination Agreement, dated the d |
|
| February 14, 2024 |
Exhibit 99.1 Adagio Medical To List on Nasdaq Through Business Combination with ARYA Sciences Acquisition Corp IV, Enabling Further Commercial and Clinical Development of Innovative Cardiac Ablation Technologies Combined Company expects to receive approximately $42 million from equity and convertible note investors at closing. LAGUNA HILLS, Calif., February 14, 2024 /PRNewswire/ - Adagio Medical, |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorpor |
|
| February 14, 2024 |
Exhibit 10.8 NOTE PURCHASE AGREEMENT THIS NOTE PURCHASE AGREEMENT (this “Agreement”) is made as of February 13, 2024, by and between Adagio Medical, Inc., a Delaware corporation (the “Company”), Aja Holdco, Inc., a Delaware corporation (“New Adagio”), and Perceptive Life Sciences Master Fund, Ltd. (the “Investor”). WHEREAS, the Company has entered into a Business Combination Agreement, dated the d |
|
| February 14, 2024 |
FORM OF CONVERTIBLE SECURITIES PURCHASE AGREEMENT Exhibit 10.7 FORM OF CONVERTIBLE SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of February [●], 2024 (the “Subscription Date”), is by and among Aja Holdco, Inc., a Delaware corporation with offices located at 51 Astor Place, 10th Floor, New York, New York 10003 (the “Company”), ARYA Sciences Acquisition Corp IV, a company organized under the laws of t |
|
| February 14, 2024 |
Exhibit 10.13 Investor Rights Agreement This Investor Rights Agreement (this “Agreement”), dated as of February 13, 2024, is among Aja Holdco, Inc., a Delaware corporation (“Company”), ARYA Sciences Acquisition Corp IV, a Cayman Islands exempted company (the “SPAC”), ARYA Sciences Holdings IV, a Cayman Islands exempted limited company (the “Sponsor”), the Independent Directors (as defined herein), |
|
| February 14, 2024 |
Exhibit 10.3 SUBSCRIPTION AGREEMENT ARYA Sciences Acquisition Corp IV 51 Astor Place, 10th Floor New York, New York 10002 Ladies and Gentlemen: This Subscription Agreement (this “Subscription Agreement”) is being entered into as of the date set forth on the signature page hereto, by and between Aja Holdco, Inc., a Delaware corporation and prior to the Closing Date (as defined below), a wholly owne |
|
| February 14, 2024 |
Exhibit 10.14 AMENDMENT TO PROMISSORY NOTE This amendment (this “Amendment”) to the convertible promissory note (the “Promissory Note”), dated February 28, 2023, by and between ARYA Sciences Acquisition Corp IV., a Cayman Islands exempted company and blank check company (the “Maker”) and ARYA Sciences Holdings IV, a Cayman Islands exempted company (the “Payee”) is made as of February 13, 2024, by |
|
| February 14, 2024 |
false0001838821NYNASDAQ00018388212024-02-132024-02-13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 14, 2024 |
FORM OF COMPANY SHAREHOLDER TRANSACTION SUPPORT AGREEMENT Exhibit 10.2 FORM OF COMPANY SHAREHOLDER TRANSACTION SUPPORT AGREEMENT This COMPANY SHAREHOLDER TRANSACTION SUPPORT AGREEMENT (this “Agreement”) is entered into as of [•], 2024, by and among ARYA Sciences Acquisition Corp IV, a Cayman Islands exempted company (“ARYA”), Adagio Medical, Inc., a Delaware corporation (the “Company”), and the party listed on the signature pages hereto as a “Shareholder |
|
| February 14, 2024 |
FORM OF COMPANY SHAREHOLDER TRANSACTION SUPPORT AGREEMENT Exhibit 10.2 FORM OF COMPANY SHAREHOLDER TRANSACTION SUPPORT AGREEMENT This COMPANY SHAREHOLDER TRANSACTION SUPPORT AGREEMENT (this “Agreement”) is entered into as of [•], 2024, by and among ARYA Sciences Acquisition Corp IV, a Cayman Islands exempted company (“ARYA”), Adagio Medical, Inc., a Delaware corporation (the “Company”), and the party listed on the signature pages hereto as a “Shareholder |
|
| February 14, 2024 |
FORM OF CONVERT SECURITY AND PLEDGE AGREEMENT Exhibit 10.11 FORM OF CONVERT SECURITY AND PLEDGE AGREEMENT SECURITY AND PLEDGE AGREEMENT, dated as of [], 2024 (this “Agreement”), made by AJA HOLDCO, INC., a corporation organized under the laws of the State of Delaware with offices located at 51 Astor Place, 10th Floor, New York, New York 10003 (the “Company”), and each of the undersigned direct and indirect and direct Subsidiaries (as defined |
|
| February 14, 2024 |
ARYD / ARYA Sciences Acquisition Corp IV / Shaolin Capital Management LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2024 |
Exhibit 99.1 Adagio Medical To List on Nasdaq Through Business Combination with ARYA Sciences Acquisition Corp IV, Enabling Further Commercial and Clinical Development of Innovative Cardiac Ablation Technologies Combined Company expects to receive approximately $42 million from equity and convertible note investors at closing. LAGUNA HILLS, Calif., February 14, 2024 /PRNewswire/ - Adagio Medical, |
|
| February 14, 2024 |
Exhibit 10.9 [FORM OF WARRANT] NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRAT |
|
| February 14, 2024 |
Exhibit 10.15 THIS CONVERTIBLE PROMISSORY NOTE (“NOTE”) AND THE SECURITIES INTO WHICH IT MAY BE CONVERTED HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE. THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED |
|
| February 14, 2024 |
TABLE OF CONTENTS Exhibit 2.1 BUSINESS COMBINATION AGREEMENT BY AND AMONG ARYA SCIENCES ACQUISITION CORP IV, AJA HOLDCO, INC., AJA MERGER SUB 1 AJA MERGER SUB 2, INC. AND ADAGIO MEDICAL, INC. DATED AS OF FEBRUARY 13, 2024 TABLE OF CONTENTS TABLE OF CONTENTS Page ARTICLE 1 CERTAIN DEFINITIONS 4 Section 1.1 Definitions 4 ARTICLE 2 MERGERS 19 Section 2.1 Closing Transactions 19 Section 2.2 Closing |
|
| February 14, 2024 |
FORM OF CONVERT SECURITY AND PLEDGE AGREEMENT Exhibit 10.11 FORM OF CONVERT SECURITY AND PLEDGE AGREEMENT SECURITY AND PLEDGE AGREEMENT, dated as of [], 2024 (this “Agreement”), made by AJA HOLDCO, INC., a corporation organized under the laws of the State of Delaware with offices located at 51 Astor Place, 10th Floor, New York, New York 10003 (the “Company”), and each of the undersigned direct and indirect and direct Subsidiaries (as defined |
|
| February 14, 2024 |
Form of Subscription Agreement with Pre-Funded Warrant and Warrant SUBSCRIPTION AGREEMENT Exhibit 10.6 Form of Subscription Agreement with Pre-Funded Warrant and Warrant SUBSCRIPTION AGREEMENT ARYA Sciences Acquisition Corp IV 51 Astor Place, 10th Floor New York, New York 10002 Ladies and Gentlemen: This Subscription Agreement (this “Subscription Agreement”) is being entered into as of the date set forth on the signature page hereto, by and between Aja Holdco, Inc., a Delaware corporat |
|
| February 14, 2024 |
Exhibit 99.2 ADAGIO MEDICAL Investor Presentation | February 2024 DISCLAIMER 2 This investor presentation (together with the oral statements made in connection herewith, this “Presentation”) is for informational purposes only to assist interested parties in making their own evaluation with respect to the proposed business combination and any related transaction, including with the PIPE financing d |
|
| February 14, 2024 |
Form of Subscription Agreement with Pre-Funded Warrant and Warrant SUBSCRIPTION AGREEMENT Exhibit 10.6 Form of Subscription Agreement with Pre-Funded Warrant and Warrant SUBSCRIPTION AGREEMENT ARYA Sciences Acquisition Corp IV 51 Astor Place, 10th Floor New York, New York 10002 Ladies and Gentlemen: This Subscription Agreement (this “Subscription Agreement”) is being entered into as of the date set forth on the signature page hereto, by and between Aja Holdco, Inc., a Delaware corporat |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorpor |
|
| February 14, 2024 |
ARYD / ARYA Sciences Acquisition Corp IV / GLAZER CAPITAL, LLC Passive Investment SC 13G/A 1 aryd20231231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 ARYA SCIENCES ACQUISITION CORP IV (Name of Issuer) Class A Ordinary Shares, $0.0001 par value per share (Title of Class of Securities) G31659108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorp |
|
| February 14, 2024 |
Form of Non-Redemption Subscription Agreement SUBSCRIPTION AGREEMENT Exhibit 10.4 Form of Non-Redemption Subscription Agreement SUBSCRIPTION AGREEMENT ARYA Sciences Acquisition Corp IV 51 Astor Place, 10th Floor New York, New York 10002 Ladies and Gentlemen: This Subscription Agreement (this “Subscription Agreement”) is being entered into as of the date set forth on the signature page hereto, by and between Aja Holdco, Inc., a Delaware corporation and prior to the |
|
| February 14, 2024 |
Exhibit 10.10 FORM OF CONVERT GUARANTY This GUARANTY, dated as of , 2024 (this “Guaranty”), is made by each of the undersigned (each a “Guarantor”, and collectively, the “Guarantors”), in favor of Allegro Management LLC, in its capacity as collateral agent (in such capacity, the “Collateral Agent” as hereinafter further defined) for the “Buyers” party to the Securities Purchase Agreement (each as |
|
| February 14, 2024 |
TABLE OF CONTENTS Exhibit 2.1 BUSINESS COMBINATION AGREEMENT BY AND AMONG ARYA SCIENCES ACQUISITION CORP IV, AJA HOLDCO, INC., AJA MERGER SUB 1 AJA MERGER SUB 2, INC. AND ADAGIO MEDICAL, INC. DATED AS OF FEBRUARY 13, 2024 TABLE OF CONTENTS TABLE OF CONTENTS Page ARTICLE 1 CERTAIN DEFINITIONS 4 Section 1.1 Definitions 4 ARTICLE 2 MERGERS 19 Section 2.1 Closing Transactions 19 Section 2.2 Closing |
|
| February 14, 2024 |
Exhibit 10.3 SUBSCRIPTION AGREEMENT ARYA Sciences Acquisition Corp IV 51 Astor Place, 10th Floor New York, New York 10002 Ladies and Gentlemen: This Subscription Agreement (this “Subscription Agreement”) is being entered into as of the date set forth on the signature page hereto, by and between Aja Holdco, Inc., a Delaware corporation and prior to the Closing Date (as defined below), a wholly owne |
|
| February 14, 2024 |
Exhibit 10.14 AMENDMENT TO PROMISSORY NOTE This amendment (this “Amendment”) to the convertible promissory note (the “Promissory Note”), dated February 28, 2023, by and between ARYA Sciences Acquisition Corp IV., a Cayman Islands exempted company and blank check company (the “Maker”) and ARYA Sciences Holdings IV, a Cayman Islands exempted company (the “Payee”) is made as of February 13, 2024, by |
|
| February 13, 2024 |
ARYD / ARYA Sciences Acquisition Corp IV / MIZUHO FINANCIAL GROUP INC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ARYA Sciences Acquisition Corp IV (Name of Issuer) Common Shares (Title of Class of Securities) G31659108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| February 13, 2024 |
EX-99.B 3 d690372dex99b.htm EX-99.B Exhibit B Power of Attorney Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and the rules and regulations thereunder, the undersigned, in the undersigned capacity as an authorized representative of Mizuho Bank, Ltd., Mizuho Americas LLC and Mizuho Securities USA LLC (collectively, the “Companies”), hereby g |
|
| February 13, 2024 |
EX-99.A 2 d690372dex99a.htm EX-99.A Exhibit A Lists of the relevant subsidiaries Subsidiary Principal business office Classification Mizuho Bank, Ltd 1–5–5, Otemachi, Chiyoda–ku, Tokyo 100–8176, Japan A non-U.S. institution equivalent to Bank Mizuho Americas LLC 1271 Avenue of the Americas, NY, NY 10020, USA A parent holding company Mizuho Securities USA LLC 1271 Avenue of the Americas, NY, NY 100 |
|
| February 9, 2024 |
Exhibit 10.1 THIS CONVERTIBLE PROMISSORY NOTE (THIS “NOTE”) AND THE SECURITIES INTO WHICH IT MAY BE CONVERTED HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE. THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFER |
|
| February 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 8, 2024 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorpora |
|
| February 9, 2024 |
ARYD / ARYA Sciences Acquisition Corp IV / PERISCOPE CAPITAL INC. - SC 13G Passive Investment SC 13G 1 d770274dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ARYA Sciences Acquisition Corp IV (Name of Issuer) Class A ordinary shares, par value $0.0001 per share (Title of Class of Securities) G31659108 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of thi |
|
| February 7, 2024 |
SC 13G/A 1 p24-0620sc13ga.htm ARYA SCIENCES ACQUISITION CORP IV SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ARYA Sciences Acquisition Corp IV (Name of Issuer) Class A Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G31659108 (CUSIP Number) December 31, 2023 (Date of Event Which Req |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2024 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorpora |
|
| February 1, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D |
|
| January 30, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2024 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorpora |
|
| January 22, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ D |
|
| January 18, 2024 |
ARYD / ARYA Sciences Acquisition Corp IV / Farallon Capital Partners, L.P. Passive Investment SC 13G/A 1 aryd13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) * ARYA Sciences Acquisition Corp IV (Name of Issuer) Class A Ordinary Shares, Par Value $0.0001 per share (Title of Class of Securities) G31659108 (Cusip Number) December 31, 2023 (Date of Event which Requires Filing of this Statemen |
|
| January 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2024 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorporat |
|
| December 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2023 (December 2, 2023) ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisd |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ARYA SCIENCES ACQUISITION CORP IV (Exact name of r |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorpora |
|
| October 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2023 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorporat |
|
| September 27, 2023 |
Exhibit 10.1 THIS PROMISSORY NOTE (“NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY |
|
| September 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 27, 2023 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorpo |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2023 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorpor |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ARYA SCIENCES ACQUISITION CORP IV (Exact name of regist |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorporati |
|
| July 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2023 (July 2, 2023) ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction o |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2023 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorporation |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ARYA SCIENCES ACQUISITION CORP IV (Exact name of regis |
|
| April 6, 2023 |
Subsidiaries of ARYA Sciences Acquisition Corp IV Exhibit 21 Subsidiaries of ARYA Sciences Acquisition Corp IV None. |
|
| April 6, 2023 |
ARYA SCIENCES ACQUISITION CORP IV DESCRIPTION OF SECURITIES Exhibit 4.2 ARYA SCIENCES ACQUISITION CORP IV DESCRIPTION OF SECURITIES The following summary of the material terms of the securities of ARYA Sciences Acquisition Corp IV is not intended to be a complete summary of the rights and preferences of such securities and is subject to and qualified by reference to our amended and restated memorandum and articles of association and applicable Cayman Islan |
|
| April 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40122 ARYA SCIENCES ACQ |
|
| April 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2023 (April 4, 2023) ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NT 10-K 1 brhc10050727nt10k.htm NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC FILE NUMBER: 001-40122 CUSIP NUMBER: G31659108 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☒ Form 10-K ☐ Form N-CSR ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Rep |
|
| March 10, 2023 |
ARYD / Arya Sciences Acquisition Corp IV - Class A / GLAZER CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 ARYA Sciences Acquisition Corp IV (Name of Issuer) Class A Ordinary Share, $0.0001 par value per share (Title of Class of Securities) G31659108 (CUSIP Number) February 28, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. ) Arya Sciences Acquisition Corp. IV (Name of Issuer) Class A Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G3165 |
|
| March 1, 2023 |
CERTIFIED EXTRACT ARYA Sciences Acquisition Corp IV (the “Company”) Exhibit 3.1 CERTIFIED EXTRACT ARYA Sciences Acquisition Corp IV (the “Company”) We, Ogier Global (Cayman) Limited, of 89 Nexus Way, Camana Bay, Grand Cayman, KY1-9009, Cayman Islands being the provider of registered office services to the Company, registered in the Cayman Islands on 24 August 2020 with Registration Number 365460, hereby certify that the foregoing is a true and correct extract of t |
|
| March 1, 2023 |
EX-10.1 3 brhc10049030ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 THIS CONVERTIBLE PROMISSORY NOTE (“NOTE”) AND THE SECURITIES INTO WHICH IT MAY BE CONVERTED HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE. THIS NOTE HAS BEEN ACQUIRED FOR INVE |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2023 (February 28, 2023) ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 (February 24, 2023) ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or ot |
|
| February 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 DEFA14A 1 brhc10048562formdefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 (February 24, 2023) ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Ca |
|
| February 14, 2023 |
SC 13G 1 aryd20221231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ARYA Sciences Acquisition Corporation IV (Name of Issuer) Class A Ordinary Share, $0.0001 par value per share (Title of Class of Securities) G31659108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check t |
|
| February 14, 2023 |
SC 13G/A 1 d994471913g-a.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)* ARYA Sciences Acquisition Corp IV (Name of Issuer) Class A Ordinary Share, $0.0001 par value (Title of Class of Securities) G31 |
|
| February 10, 2023 |
DEF 14A 1 ny20007121x2def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission |
|
| January 31, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ D |
|
| January 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 7, 2022 |
Exhibit 10.1 THIS CONVERTIBLE PROMISSORY NOTE (?NOTE?) AND THE SECURITIES INTO WHICH IT MAY BE CONVERTED HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?) OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE. THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2022 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorpora |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ARYA SCIENCES ACQUISITION CORP IV (Exact name of r |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ARYA SCIENCES ACQUISITION CORP IV (Exact name of regist |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ARYA SCIENCES ACQUISITION CORP IV (Exact name of regis |
|
| March 31, 2022 |
Subsidiaries of ARYA Sciences Acquisition Corp IV Exhibit 21 Subsidiaries of ARYA Sciences Acquisition Corp IV None. |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ARYA SCIENCES ACQUISITION CORP IV (Exact name of re |
|
| February 24, 2022 |
Exhibit 10.1 TERMINATION AGREEMENT This TERMINATION AGREEMENT (the ?Agreement?), dated as of February 23, 2022, is made by and between ARYA Sciences Acquisition Corp IV (?ARYA?) and Amicus Therapeutics, Inc. (the ?Company?). W I T N E S E T H: WHEREAS, ARYA and the Company entered into that certain Business Combination Agreement, dated as of September 29, 2021 (the ?Combination Agreement?), by and |
|
| February 24, 2022 |
ARYA Sciences Acquisition Corp IV 51 Astor Place, 10th Floor New York, NY 10003 February 24, 2022 RW 1 brhc10034375rw.htm RW ARYA Sciences Acquisition Corp IV 51 Astor Place, 10th Floor New York, NY 10003 February 24, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Trade & Services 100 F Street, N.E. Washington, D.C. 20549 Attention: Jessica Ansart and Joe McCann Re: ARYA Sciences Acquisition Corp IV Request for Withdrawal of Registration Statement o |
|
| February 24, 2022 |
EX-99.1 3 brhc10034373ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ARYA SCIENCES ACQUISITION CORP IV AND AMICUS THERAPEUTICS, INC. MUTUALLY AGREE TO TERMINATE BUSINESS COMBINATION AGREEMENT WITH RESPECT TO THE ACQUISITION OF AMICUS’ GENE THERAPY BUSINESS DUE TO MARKET CONDITIONS NEW YORK – February 24, 2022 – ARYA Sciences Acquisition Corp IV (NASDAQ: ARYD) (“ARYA IV”), a publicly traded special purpose a |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 23, 2022 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorpor |
|
| February 14, 2022 |
SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 1)* ARYA Sciences Acquisition Corp IV (Name of Issuer) Class A Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G31659108 (CUSIP Number |
|
| February 14, 2022 |
EX-1 2 brhc10033870ex1.htm EXHIBIT 1 EXHIBIT 1 JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Class A ordinary shares, par value $0.0001 per share, of ARYA Sciences Acquisition Corp IV (this “Agre |
|
| February 14, 2022 |
JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EXHIBIT I JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* ARYA Sciences Acquisition Corp IV (Name of Issuer) Class A ordinary shares, $0.0001 par value per share (Title of Class of Securities) G31659108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the Appropriate |
|
| February 14, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ARYA SCIENCES ACQUISITION CORP IV (Name of Issuer) Class A Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G31659108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| January 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 13, 2022 |
ARYA SCIENCES ACQUISITION CORP IV Exhibit 99.1 ARYA SCIENCES ACQUISITION CORP IV Report of Independent Registered Public Accounting Firm F-2 Balance Sheet (As Restated) F-3 Notes to Financial Statement (As Restated) F-4 Report of Independent Registered Public Accounting Firm To the Shareholders and the Board of Directors of ARYA Sciences Acquisition Corp IV Opinion on the Financial Statement We have audited the accompanying balanc |
|
| January 13, 2022 |
Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 8, 2021 (March 2, 2021) ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorpor |
|
| December 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ARYA SCIENCES ACQUISITION CORP |
|
| December 7, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 1, 2021 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands 001-40122 98-1574672 (State or other jurisdiction of incorporation or organi |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* ARYA Sciences Acquisition Corp IV. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) G31659108 (CUSIP Number) November 15, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ARYA SCIENCES ACQUISITION CORP IV (Exact name of r |
|
| November 1, 2021 |
As filed with the U.S. Securities and Exchange Commission on October 29, 2021 As filed with the U.S. Securities and Exchange Commission on October 29, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARYA SCIENCES ACQUISITION CORP IV* (Exact name of registrant as specified in its charter) Cayman Islands* 6770 98-1574672 (State or other Jurisdiction of Incorpora |
|
| November 1, 2021 |
Exhibit 10.12 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this ?Agreement?) is made as of [?], 2021, by and between Caritas Therapeutics, Inc., a Delaware corporation (the ?Corporation?), and [?] (?Indemnitee?). WHEREAS, highly competent persons have become more reluctant to serve publicly held corporations as directors, officers or in other capacities unless they are provided with adequate prot |
|
| November 1, 2021 |
List of Subsidiaries of ARYA Sciences Acquisition Corp IV EX-21.1 3 ny20001065x1-211.htm EXHIBIT 21.1 Exhibit 21.1 List of Subsidiaries of ARYA Sciences Acquisition Corp IV None. |
|
| October 5, 2021 |
SC 13G 1 d229113dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ARYA SCIENCES ACQUISITION CORP IV (Name of Issuer) Class A Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G31659108 (CUSIP Number) September 29, 2021 (Date of Event Which Requires Filing of th |
|
| September 29, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 29, 2021 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands (State or other jurisdiction of incorporation or organization) 001-40122 |
|
| September 29, 2021 |
Exhibit 10.1 Execution Version SPONSOR LETTER AGREEMENT This SPONSOR LETTER AGREEMENT (this ?Agreement?), dated as of September 29, 2021, is made by and among ARYA Sciences Holdings IV, an exempted company incorporated in the Cayman Islands with limited liability (the ?ARYA Sponsor?), ARYA Sciences Acquisition Corp IV, an exempted company incorporated in the Cayman Islands with limited liability ( |
|
| September 29, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 29, 2021 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands (State or other jurisdiction of incorporation or organization) 001-40122 |
|
| September 29, 2021 |
Exhibit 2.1 Execution Version BUSINESS COMBINATION AGREEMENT DATED SEPTEMBER 29, 2021 BY AND AMONG ARYA SCIENCES ACQUISITION CORP IV, AMICUS THERAPEUTICS, INC., AMICUS GT HOLDINGS, LLC AND CARITAS THERAPEUTICS, LLC TABLE OF CONTENTS Page Article I DEFINITIONS 4 Article II BUSINESS COMBINATION 29 2.1 Closing Transactions 29 2.2 Closing; Closing Date 30 2.3 Withholding 30 Article III REPRESENTATIONS |
|
| September 29, 2021 |
Exhibit 99.1 Amicus Therapeutics and ARYA Sciences Acquisition Corp IV Announce Formation of a Next-Generation Genetic Medicine Company: ?Caritas Therapeutics? Business Combination of Amicus Gene Therapy Business with ARYA IV to Result in the Launch of Caritas Therapeutics, a New Independent, Publicly Traded Company with Expected ~$400M in Initial Funding Will Transform Amicus into a Premier Globa |
|
| September 29, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 29, 2021 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands (State or other jurisdiction of incorporation or organization) 001-40122 ( |
|
| September 29, 2021 |
? Exhibit 10.2 ? Execution Version ? Investor Rights Agreement ? This Investor Rights Agreement (this ?Agreement?), dated as of September 29, 2021, is among ARYA Sciences Acquisition Corp IV, a Cayman Islands exempted company (the ?Company?) and the other parties hereto identified as a ?Holder? on the signature pages hereto (each, a ?Holder? and collectively, the ?Holders?). Capitalized terms used |
|
| September 29, 2021 |
Exhibit 99.3 Operator: Thank you for joining our call today. In this call we?ll be discussing information contained in our press release issued today. Before we discuss what we believe is a very exciting announcement and a significant milestone for both Caritas Therapeutics and Arya IV, I will make some important disclaimers. Please note that today?s presentation is neither an offering of securiti |
|
| September 29, 2021 |
425 1 tm2128759d4425.htm 425 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 29, 2021 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands (State or other jurisdiction of incorporation |
|
| September 29, 2021 |
Harnessing the Power of Genetic Medicine September 2021 Investor Presentation CONFIDENTIAL Exhibit 99.2 Harnessing the Power of Genetic Medicine September 2021 Investor Presentation CONFIDENTIAL 2 CONFIDENTIAL Disclaimer This presentation contains proprietary and confidential information of Amicus Therapeutics, Inc . ?s gene therapy business (?Caritas?) and ARYA Science Acquisition Corp IV (?ARYA?), and the entire content should be considered ?Confidential Information . ? Neither ARYA, |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ARYA SCIENCES ACQUISITION CORP IV (Exact name of regist |
|
| May 13, 2021 |
Description of Registrant’s Securities(3) Exhibit 4.2 ARYA SCIENCES ACQUISITION CORP IV DESCRIPTION OF SECURITIES The following summary of the material terms of the securities of ARYA Sciences Acquisition Corp IV is not intended to be a complete summary of the rights and preferences of such securities and is subject to and qualified by reference to our amended and restated memorandum and articles of association and applicable Cayman Islan |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ARYA SCIENCES ACQUISITION CORP IV (Exact name of regis |
|
| May 10, 2021 |
JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) EXHIBIT 1 to SCHEDULE 13G JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition st |
|
| May 10, 2021 |
SC 13G 1 tm2115565d2sc13g.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) * ARYA Sciences Acquisition Corp IV (Name of Issuer) Class A Ordinary Shares, Par Value $0.0001 per share (Title of Class of Securities) G31659108 (Cusip Number) March 2, 2021 (Date of Event which Requires Filing of |
|
| March 12, 2021 |
ARYA Sciences Acquisition Corp IV SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ARYA Sciences Acquisition Corp IV (Name of Issuer) Class A Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G31659108 (CUSIP Number) March 2, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate |
|
| March 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ARYA Sciences Acquisition Corp IV (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) G31659108 (CUSIP Number) March 2, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| March 8, 2021 |
SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. )* ARYA Sciences Acquisition Corp IV (Name of Issuer) Class A Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G31659108 (CUSIP Number |
|
| March 8, 2021 |
ARYA SCIENCES ACQUISITION CORP IV Exhibit 99.1 ARYA SCIENCES ACQUISITION CORP IV Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Financial Statement F-4 F-1 Report of Independent Registered Public Accounting Firm To the Shareholders and the Board of Directors of ARYA Sciences Acquisition Corp IV Opinion on the Financial Statements We have audited the accompanying balance sheet of ARYA Science |
|
| March 8, 2021 |
Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 8, 2021 (March 2, 2021) ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands (State or other jurisdiction of incorporation or organization) |
|
| March 2, 2021 |
8-K 1 nt10018811x98k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 2, 2021 (February 25, 2021) ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands (State or other |
|
| March 2, 2021 |
Exhibit 10.3 REGISTRATION AND SHAREHOLDER RIGHTS AGREEMENT THIS REGISTRATION AND SHAREHOLDER RIGHTS AGREEMENT (this ?Agreement?), dated as of March 2, 2021, is made and entered into by and among ARYA Sciences Acquisition Corp IV, a Cayman Islands exempted company (the ?Company?), ARYA Sciences Holdings IV, a Cayman Island exempted limited company (the ?Sponsor?), and the undersigned parties listed |
|
| March 2, 2021 |
Exhibit 10.2 INVESTMENT MANAGEMENT TRUST AGREEMENT This Investment Management Trust Agreement (this ?Agreement?) is made effective as of March 2, 2021 by and between ARYA Sciences Acquisition Corp IV, a Cayman Islands exempted company (the ?Company?), and Continental Stock Transfer & Trust Company, a New York corporation (the ?Trustee?). WHEREAS, the Company?s registration statement on Form S-1, F |
|
| March 2, 2021 |
Letter Agreement among the Company, the Sponsor and the Company’s officers and directors.(1) Exhibit 10.4 February 25, 2021 ARYA Sciences Acquisition Corp IV 51 Astor Place, 10th Floor New York, New York 10003 Re: Initial Public Offering Ladies and Gentlemen: This letter (this ?Letter Agreement?) is being delivered to you in accordance with the Underwriting Agreement (the ?Underwriting Agreement?) entered into by and among ARYA Sciences Acquisition Corp IV, a Cayman Islands exempted compa |
|
| March 2, 2021 |
Administrative Services Agreement between the Company and the Sponsor.(1) Exhibit 10.5 ARYA SCIENCES ACQUISITION CORP IV 51 Astor Place, 10th Floor New York, New York 10003 March 2, 2021 ARYA Sciences Holdings IV c/o Perceptive Advisors 51 Astor Place, 10th Floor New York, New York 10003 Ladies and Gentlemen: This letter will confirm our agreement that, commencing on the effective date (the ?Effective Date?) of the registration statement (the ?Registration Statement?) f |
|
| March 2, 2021 |
13,000,000 Class A Ordinary Shares ARYA Sciences Acquisition Corp IV UNDERWRITING AGREEMENT Exhibit 1.1 EXECUTION VERSION 13,000,000 Class A Ordinary Shares ARYA Sciences Acquisition Corp IV UNDERWRITING AGREEMENT February 25, 2021 GOLDMAN SACHS & CO. LLC JEFFERIES LLC As Representatives of the several Underwriters c/o GOLDMAN SACHS & CO. LLC 200 West Street New York, New York 10282 c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Introductory. ARYA Sci |
|
| March 2, 2021 |
Amended and Restated Memorandum and Articles of Association.(1) Exhibit 3.1 Companies Act (Revised) Company Limited by Shares AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION OF ARYA SCIENCES ACQUISITION CORP IV Adopted by special resolution on 24 February 2021 www.verify.gov.ky File#: 365460 Filed: 25-Feb-2021 13:59 EST Auth Code: B82728819794 Companies Act (Revised) Company Limited by Shares Amended and Restated Memorandum of Association of ARYA Sciences Acqui |
|
| March 2, 2021 |
Private Placement Shares Purchase Agreement between the Company and the Sponsor.(1) Exhibit 10.1 PRIVATE PLACEMENT SHARES PURCHASE AGREEMENT THIS PRIVATE PLACEMENT SHARES PURCHASE AGREEMENT (as it may from time to time be amended and including all exhibits referenced herein, this ?Agreement?), dated as of February 25, 2021, is entered into by and between ARYA Sciences Acquisition Corp IV, a Cayman Islands exempted company (the ?Company?), and ARYA Sciences Holdings IV, a Cayman I |
|
| March 1, 2021 |
$130,000,000 ARYA Sciences Acquisition Corp IV 13,000,000 Class A Ordinary Shares TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(4) Registration No. 333-252960 PROSPECTUS $130,000,000 ARYA Sciences Acquisition Corp IV 13,000,000 Class A Ordinary Shares ARYA Sciences Acquisition Corp IV is a newly organized blank check company incorporated as a Cayman Islands exempted company and formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, re |
|
| February 25, 2021 |
8-A12B 1 nt10018811x48a12b.htm 8-A12B SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 ARYA SCIENCES ACQUISITION CORP IV (Exact name of registrant as specified in its charter) Cayman Islands (State or other jurisdiction of incorporation or organization) 98-1 |
|
| February 19, 2021 |
As filed with the United States Securities and Exchange Commission on February 19, 2021 under the Securities Act of 1933, as amended. |
|
| February 19, 2021 |
INVESTMENT MANAGEMENT TRUST AGREEMENT Exhibit 10.1 INVESTMENT MANAGEMENT TRUST AGREEMENT This Investment Management Trust Agreement (this ?Agreement?) is made effective as of February [?], 2021 by and between ARYA Sciences Acquisition Corp IV, a Cayman Islands exempted company (the ?Company?), and Continental Stock Transfer & Trust Company, a New York corporation (the ?Trustee?). WHEREAS, the Company?s registration statement on Form S |
|
| February 19, 2021 |
Exhibit 3.2 Dated [ ] 2021 Companies Act (Revised) Company Limited by Shares amended and restated memorandum of association OF ARYA Sciences Acquisition Corp IV Adopted by special resolution on [ ] 2021 Companies Act (Revised) Company Limited by Shares Amended and Restated Memorandum of Association of ARYA Sciences Acquisition Corp IV Adopted by special resolution on [ ] 2021 1 The name of the Com |
|
| February 19, 2021 |
Exhibit 3.1 Dated the 24th of August, 2020. Companies Law (Revised) Company Limited by Shares MEMORANDUM OF ASSOCIATION OF ARYA SCIENCES ACQUISITION CORP IV Auth Code: E27877513171 www.verify.gov.ky Companies Law (Revised) Company Limited by Shares Memorandum of Association of ARYA Sciences Acquisition Corp IV 1 The name of the Company is ARYA Sciences Acquisition Corp IV. 2 The Company?s register |
|
| February 19, 2021 |
Specimen Ordinary Share Certificate.(2) Exhibit 4.1 SPECIMEN CLASS A ORDINARY SHARE CERTIFICATE NUMBER SHARES ARYA SCIENCES ACQUISITION CORP IV INCORPORATED UNDER THE LAWS OF THE CAYMAN ISLANDS CLASS A ORDINARY SHARES SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP [?] This Certifies that is the owner of FULLY PAID AND NON-ASSESSABLE CLASS A ORDINARY SHARES OF THE PAR VALUE OF US $0.0001 EACH OF ARYA SCIENCES ACQUISITION CORP IV (THE ?COMPANY |
|
| February 19, 2021 |
13,000,000 Class A Ordinary Shares ARYA Sciences Acquisition Corp IV UNDERWRITING AGREEMENT Exhibit 1.1 13,000,000 Class A Ordinary Shares ARYA Sciences Acquisition Corp IV UNDERWRITING AGREEMENT [ ], 2021 GOLDMAN SACHS & CO. LLC JEFFERIES LLC As Representatives of the several Underwriters c/o GOLDMAN SACHS & CO. LLC 200 West Street New York, New York 10282 c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Introductory. ARYA Sciences Acquisition Corp IV, |
|
| February 19, 2021 |
Exhibit 10.7 ARYA Sciences Acquisition Corp IV c/o Perceptive Advisors 51 Astor Place, 10th Floor New York, NY 10003 January 4, 2020 ARYA Sciences Holdings IV c/o Perceptive Advisors 51 Astor Place, 10th Floor New York, NY 10003 RE: Securities Subscription Agreement Gentlemen: This agreement (this ?Agreement?) is entered into on January 4, 2020 by and between ARYA Sciences Holdings IV, a Cayman Is |
|
| February 19, 2021 |
Form of Indemnity Agreement.(2) Exhibit 10.4 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this ?Agreement?) is made as of February [?], 2021, by and between ARYA Sciences Acquisition Corp IV, a Cayman Islands exempted company (the ?Company?), and (?Indemnitee?). WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as directors, officers or in other capacities unless they are provided |
|
| February 19, 2021 |
Exhibit 10.5 ARYA SCIENCES ACQUISITION CORP IV 51 Astor Place, 10th Floor New York, New York 10003 February [?], 2021 ARYA Sciences Holdings IV c/o Perceptive Advisors 51 Astor Place, 10th Floor New York, New York 10003 Ladies and Gentlemen: This letter will confirm our agreement that, commencing on the effective date (the ?Effective Date?) of the registration statement (the ?Registration Statemen |
|
| February 19, 2021 |
REGISTRATION AND SHAREHOLDER RIGHTS AGREEMENT Exhibit 10.2 REGISTRATION AND SHAREHOLDER RIGHTS AGREEMENT THIS REGISTRATION AND SHAREHOLDER RIGHTS AGREEMENT (this ?Agreement?), dated as of February [?], 2021, is made and entered into by and among ARYA Sciences Acquisition Corp IV, a Cayman Islands exempted company (the ?Company?), ARYA Sciences Holdings IV, a Cayman Island exempted limited company (the ?Sponsor?), and the undersigned parties l |
|
| February 19, 2021 |
Exhibit 10.8 February [?], 2021 ARYA Sciences Acquisition Corp IV 51 Astor Place, 10th Floor New York, New York 10003 Re: Initial Public Offering Ladies and Gentlemen: This letter (this ?Letter Agreement?) is being delivered to you in accordance with the Underwriting Agreement (the ?Underwriting Agreement?) entered into by and among ARYA Sciences Acquisition Corp IV, a Cayman Islands exempted comp |
|
| February 19, 2021 |
PRIVATE PLACEMENT SHARES PURCHASE AGREEMENT Exhibit 10.3 PRIVATE PLACEMENT SHARES PURCHASE AGREEMENT THIS PRIVATE PLACEMENT SHARES PURCHASE AGREEMENT (as it may from time to time be amended and including all exhibits referenced herein, this ?Agreement?), dated as of February [?], 2021, is entered into by and between ARYA Sciences Acquisition Corp IV, a Cayman Islands exempted company (the ?Company?), and ARYA Sciences Holdings IV, a Cayman |
|
| February 19, 2021 |
Exhibit 10.6 THIS PROMISSORY NOTE (?NOTE?) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY |
|
| February 10, 2021 |
EX-99.3 5 nt10018811x2ex99-3.htm EXHIBIT 99.3 Exhibit 99.3 CONSENT OF MICHAEL HENDERSON ARYA Sciences Acquisition Corp IV (the “Company”) intends to file a Registration Statement on Form S-1 (together with any amendments or supplements thereto, the “Registration Statement”) registering securities for issuance in its initial public offering. As required by Rule 438 under the Securities Act of 1933, |
|
| February 10, 2021 |
Exhibit 99.1 CONSENT OF TODD WIDER ARYA Sciences Acquisition Corp IV (the “Company”) intends to file a Registration Statement on Form S-1 (together with any amendments or supplements thereto, the “Registration Statement”) registering securities for issuance in its initial public offering. As required by Rule 438 under the Securities Act of 1933, as amended, the undersigned hereby consents to being |
|
| February 10, 2021 |
S-1 1 nt10018811x2s1.htm S-1 TABLE OF CONTENTS As filed with the United States Securities and Exchange Commission on February 10, 2021 under the Securities Act of 1933, as amended. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ARYA Sciences Acquisition Corp IV (Exact name of regist |
|
| February 10, 2021 |
EX-99.2 4 nt10018811x2ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 CONSENT OF LESLIE TRIGG ARYA Sciences Acquisition Corp IV (the “Company”) intends to file a Registration Statement on Form S-1 (together with any amendments or supplements thereto, the “Registration Statement”) registering securities for issuance in its initial public offering. As required by Rule 438 under the Securities Act of 1933, as a |
|
| January 13, 2021 |
DRS 1 filename1.htm TABLE OF CONTENTS As submitted confidentially with the U.S. Securities and Exchange Commission on January 13, 2021. This draft registration statement has not been publicly filed with the U.S. Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20 |
